Literature DB >> 15762880

Relationship of granulocyte colony stimulating factor with other acute phase reactants in man.

M Noursadeghi1, M B Pepys, R Gallimore, J Cohen.   

Abstract

The non-specific acute phase response in mice is associated with increased resistance to bacterial infection, which is critically mediated by granulocyte colony stimulating factor (G-CSF), but the behaviour of G-CSF in the human acute phase response is not known. Cardiothoracic surgery is a powerful acute phase stimulus and we show here that this procedure caused increased production of G-CSF, in addition to increases in the circulating concentrations of the proinflammatory cytokine interleukin (IL)-6 and the acute phase plasma proteins C-reactive protein (CRP) and serum amyloid A protein (SAA). Values of G-CSF correlated positively with IL-6 concentrations and circulating neutrophil counts, but not with CRP values. These results confirm that G-CSF is a physiological component of the acute phase response in humans that shares some of the same regulatory controls as IL-6, but its downstream effects are on neutrophils, not hepatic acute phase protein synthesis. Our observations are compatible with a protective role against bacterial infection for G-CSF in the human acute phase response, and support investigation of the prophylactic use of G-CSF in at-risk patients.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 15762880      PMCID: PMC1809334          DOI: 10.1111/j.1365-2249.2005.02732.x

Source DB:  PubMed          Journal:  Clin Exp Immunol        ISSN: 0009-9104            Impact factor:   4.330


  26 in total

1.  Cardiopulmonary bypass elicits a pro- and anti-inflammatory cytokine response and impaired neutrophil chemotaxis in neonatal pigs.

Authors:  V Brix-Christensen; T K Petersen; H B Ravn; V E Hjortdal; N T Andersen; E Tønnesen
Journal:  Acta Anaesthesiol Scand       Date:  2001-04       Impact factor: 2.105

2.  C-reactive protein in patients undergoing cardiac surgery.

Authors:  H Boralessa; F C de Beer; A Manchie; J G Whitwam; M B Pepys
Journal:  Anaesthesia       Date:  1986-01       Impact factor: 6.955

3.  Neutrophilia and granulocyte colony-stimulating factor levels after cardiopulmonary bypass.

Authors:  H Iwasaka; T Kitano; H Miyakawa; M Unoshima; C Shinguu; S Matsumoto; T Noguchi
Journal:  Can J Anaesth       Date:  2001-01       Impact factor: 5.063

4.  Efficacy of recombinant human granulocyte colony-stimulating factor in a murine model of pneumococcal pneumonia: effects of lung inflammation and timing of treatment.

Authors:  F Dallaire; N Ouellet; M Simard; Y Bergeron; M G Bergeron
Journal:  J Infect Dis       Date:  2000-11-15       Impact factor: 5.226

5.  Levels of serum granulocyte colony-stimulating factor in patients with infections.

Authors:  M Kawakami; H Tsutsumi; T Kumakawa; H Abe; M Hirai; S Kurosawa; M Mori; M Fukushima
Journal:  Blood       Date:  1990-11-15       Impact factor: 22.113

6.  Multicenter, double-blind, placebo-controlled study of the use of filgrastim in patients hospitalized with pneumonia and severe sepsis.

Authors:  Richard K Root; Robert F Lodato; Ward Patrick; John Francis Cade; Nick Fotheringham; Steven Milwee; Jean-Louis Vincent; Antonio Torres; Jordi Rello; Steve Nelson
Journal:  Crit Care Med       Date:  2003-02       Impact factor: 7.598

7.  Attenuation of the bacterial load in blood by pretreatment with granulocyte-colony-stimulating factor protects rats from fatal outcome and brain damage during Streptococcus pneumoniae meningitis.

Authors:  Christian T Brandt; Jens D Lundgren; Søren Peter Lund; Niels Frimodt-Møller; Thomas Christensen; Thomas Benfield; Frank Espersen; David M Hougaard; Christian Østergaard
Journal:  Infect Immun       Date:  2004-08       Impact factor: 3.441

8.  Kinetics of procalcitonin, interleukin 6 and C-reactive protein after cardiopulmonary-bypass in children.

Authors:  Maurice Beghetti; Peter C Rimensberger; Afksendiyos Kalangos; Walid Habre; Alain Gervaix
Journal:  Cardiol Young       Date:  2003-04       Impact factor: 1.093

9.  Production of granulocyte colony-stimulating factor in the nonspecific acute phase response enhances host resistance to bacterial infection.

Authors:  Mahdad Noursadeghi; Maria C M Bickerstaff; Jeff Herbert; David Moyes; Jonathan Cohen; Mark B Pepys
Journal:  J Immunol       Date:  2002-07-15       Impact factor: 5.422

10.  A nuclear factor for IL-6 expression (NF-IL6) is a member of a C/EBP family.

Authors:  S Akira; H Isshiki; T Sugita; O Tanabe; S Kinoshita; Y Nishio; T Nakajima; T Hirano; T Kishimoto
Journal:  EMBO J       Date:  1990-06       Impact factor: 11.598

View more
  8 in total

1.  Susceptibility to quantum dot induced lung inflammation differs widely among the Collaborative Cross founder mouse strains.

Authors:  David K Scoville; Collin C White; Dianne Botta; Lisa A McConnachie; Megan E Zadworny; Stefanie C Schmuck; Xiaoge Hu; Xiaohu Gao; Jianbo Yu; Russell L Dills; Lianne Sheppard; Martha A Delaney; William C Griffith; Richard P Beyer; Richard C Zangar; Joel G Pounds; Elaine M Faustman; Terrance J Kavanagh
Journal:  Toxicol Appl Pharmacol       Date:  2015-10-21       Impact factor: 4.219

2.  Disentangling the effects of tocilizumab on neutrophil survival and function.

Authors:  Timo Gaber; Martin Hahne; Cindy Strehl; Paula Hoff; Yvonne Dörffel; Eugen Feist; Gerd-Rüdiger Burmester; Frank Buttgereit
Journal:  Immunol Res       Date:  2016-06       Impact factor: 2.829

3.  Does granulocyte-colony stimulating factor administration induce damage or repair response in schistosomiasis?

Authors:  Lobna Y Ghanem; Uta Dahmen; Olaf Dirsch; Mona Mf Nosseir; Soheir S Mahmoud; Wafaa Af Mansour
Journal:  World J Hepatol       Date:  2010-12-27

4.  Expression of nuclear factor -κBp65 in mononuclear cells in Kawasaki disease and its relation to coronary artery lesions.

Authors:  Wei Yin; Xiang Wang; Yan Ding; Hua Peng; Ya-Li Liu; Rui-Geng Wang; Ya-Ling Yang; Jun-Hui Xiong; Shi-Xiu Kang
Journal:  Indian J Pediatr       Date:  2011-06-18       Impact factor: 1.967

5.  Severe neutrophilic leukocytosis as a progression marker in granulocyte colony-stimulating factor-producing squamous cell carcinoma of the esophagus.

Authors:  Shun Yamaguchi; Kengo Kanetaka; Shinichiro Kobayashi; Yasuhiro Nagata; Naoe Kinosita; Junya Fukuoka; Shunsuke Murakami; Fumihiko Fujita; Mitsuhisa Takatsuki; Susumu Eguchi
Journal:  Clin Case Rep       Date:  2017-03-31

Review 6.  The immunopathology of sepsis: pathogen recognition, systemic inflammation, the compensatory anti-inflammatory response, and regulatory T cells.

Authors:  D H Lewis; D L Chan; D Pinheiro; E Armitage-Chan; O A Garden
Journal:  J Vet Intern Med       Date:  2012-03-17       Impact factor: 3.333

Review 7.  Therapeutic targets in rheumatoid arthritis: the interleukin-6 receptor.

Authors:  Jean-Michel Dayer; Ernest Choy
Journal:  Rheumatology (Oxford)       Date:  2009-10-23       Impact factor: 7.580

8.  IL-6 receptor inhibition with tocilizumab improves treatment outcomes in patients with rheumatoid arthritis refractory to anti-tumour necrosis factor biologicals: results from a 24-week multicentre randomised placebo-controlled trial.

Authors:  P Emery; E Keystone; H P Tony; A Cantagrel; R van Vollenhoven; A Sanchez; E Alecock; J Lee; J Kremer
Journal:  Ann Rheum Dis       Date:  2008-07-14       Impact factor: 19.103

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.